NCT03288012View on ClinicalTrials.gov

Sickle Cell Disease: Targeting Alloantibody Formation Reduction; Risk Factors, and Genetics

UnknownOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

September 20, 2017

Primary Completion Date

June 1, 2021

Study Completion Date

December 31, 2021

Conditions
AlloimmunizationSickle Cell Disease
Trial Locations (4)

Unknown

RECRUITING

Academic Medical Center Amsterdam, Amsterdam-Zuidoost

RECRUITING

Radboudumc, Nijmegen

RECRUITING

Erasmus MC, Rotterdam

NOT_YET_RECRUITING

HagaZiekenhuis, The Hague

Sponsors

Collaborators (1)

Erasmus Medical Center
All Listed Sponsors
collaborator

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

collaborator

Radboud University Medical Center

OTHER

collaborator

HagaZiekenhuis

OTHER

collaborator

Erasmus Medical Center

OTHER

lead

Sanquin Research & Blood Bank Divisions

OTHER